Komori
Rohto Pharmaceutical (4527) · RiskMitigated

Demand, supply chain and financial market risks arising from COVID-19

First written in FY2020. 8 of 15 entries say "Mitigated", first in FY2022-Q3. Latest entry: FY2024.

15entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMaterialisedFY2021-Q1 – FY2022-Q2MitigatedFY2022-Q3 – FY20242020: 320202021: 420212022: 320222023: 320232024: 22024
Same theme, other companies
Risk of COVID-19 impacts on business activities, supply chains, demand and financial performanceA theme 1346 companies write about · 1357 as a headwind · 6 as a tailwind

The whole theme swung hardest in 2020: 102 of 175 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 1371 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024MitigatedAnnual report

    「During the first 3 quarters of the fiscal year, Japan's economy was on a recovery path as economic activity normalised further following the lifting of restrictions imposed in response to COVID-19, helped also by an increase in overseas visitors.」

    The lifting of restrictions on movement and the increase in travelers normalized economic activity, further reducing the impact of COVID-19 on demand and the business environment.
  2. FY2024-Q3MitigatedAnnual report

    「During the first 3 quarters of the fiscal year, Japan's economy was on a recovery path as economic activity normalised further following the lifting of restrictions imposed in response to COVID-19, helped also by an increase in overseas visitors.」

    The lifting of COVID-19-related restrictions on movement, the normalization of economic activity and the increase in overseas travelers further reduced the impact on demand and the business environment.
  3. FY2024-Q2MitigatedAnnual report

    「During the cumulative second quarter of the current consolidated fiscal year, economic activity in Japan entered a gradual recovery trend as restrictions on behavior were eased following the reclassification of the novel coronavirus disease as a Class 5 infectious disease, while the number of visitors from overseas also increased.」

    The transition of COVID-19 to Category 5, the easing of restrictions on movement and the increase in travelers put economic activity on a recovery trend, reducing the impact on demand and the business environment compared with the previous year.
  4. FY2024-Q1MitigatedAnnual report

    「During the cumulative first quarter of the current consolidated fiscal year, the Japanese economy showed signs of a gradual recovery in economic activity as the novel coronavirus disease was reclassified as a Class 5 infectious disease, restrictions on behavior were eased and human mobility increased, although」

    The transition of COVID-19 to Category 5 under Japan's infectious disease classification and the easing of restrictions on movement led to a recovery in foot traffic and economic activity, reducing the impact on demand and the business environment compared with the previous year.
  5. FY2023MitigatedAnnual report

    「During the current consolidated fiscal year, the spread of variants of the novel coronavirus continued to have an impact, but economic activity showed some signs of improvement as restrictions on behavior were eased.」

    Although the impact of COVID-19 continued, the easing of restrictions on movement and the recovery of economic activity reduced its impact on demand and sales compared with the previous year.
  6. FY2023-Q2MitigatedAnnual report

    「Although revenue fell sharply in the same period of the previous year because of COVID-19, revenue increased significantly in the current period. Despite the impact of the renewed spread of infections caused by new variants, the progress of vaccinations led to the resumption of economic activity and signs of recovery in consumer sentiment.」

    While the impact of renewed spread caused by variants continued, vaccinations and the resumption of economic activity reduced the impact on demand and sales compared with the same period of the previous year.
  7. FY2023-Q1MitigatedAnnual report

    「In Japan, sales increased as consumer sentiment recovered following the progress of vaccinations and the resumption of economic activity, as well as through product proposals tailored to customer needs. Overseas, sales also increased as economic activity recovered, despite surging raw material prices and sharp exchange-rate fluctuations.」

    Although the impact of COVID-19 continued, vaccinations and the resumption of economic activity reduced its impact on consumption and sales in Japan and overseas compared with the same period of the previous year.
  8. FY2022-Q3MitigatedAnnual report

    「Although revenue fell sharply in the same period of the previous year because of COVID-19, vaccinations progressed in the current period, and economic activity resumed in many countries, with signs of recovery in consumer sentiment.」

    Although the impact of COVID-19 continued, the company reported a period in which vaccinations and the resumption of economic activity reduced the impact on demand and sales compared with the same period of the previous year.
  9. FY2022-Q2MaterialisedAnnual report

    「Although revenue fell sharply in the same period of the previous year because of COVID-19, revenue increased significantly in the current period. Despite the impact of the renewed spread of infections caused by new variants, the progress of vaccinations led to the resumption of economic activity and signs of recovery in consumer sentiment.」

    While the impact of renewed spread caused by COVID-19 variants continued, vaccinations and the resumption of economic activity led to signs of recovery in consumer sentiment, resulting in a significant increase in revenue from the same period of the previous year.
  10. FY2022-Q1MaterialisedAnnual report

    「In Japan, sales increased despite the impact of the renewed spread of COVID-19, as consumer sentiment showed signs of recovery due to pandemic fatigue. Overseas, although concerns remained about the spread of infection caused by variants, some regions showed signs of recovery as COVID-19 vaccinations progressed.」

    While concerns about the renewed spread of COVID-19 and variants continued, the company also reported a recovery in consumer sentiment and signs of recovery in overseas regions as vaccinations progressed.
  11. FY2021MaterialisedAnnual report

    「Sales declined because of the impact of the resurgence of COVID-19 and the entrenchment of mask-wearing culture. Overseas, sales also declined in every region because of the global spread of COVID-19.」

    Restrictions on going out, mask-wearing culture and activity restrictions in overseas regions materialized as lower sales in Japan and overseas for the full year.
  12. FY2021-Q3MaterialisedAnnual report

    「During the cumulative third quarter of the current consolidated fiscal year, a severe business environment continued, with economic activity restricted by the resurgence of the novel coronavirus disease. Personal consumption also remained in an uncertain environment, as consumer sentiment continued to deteriorate.」

    Restrictions on economic activity, weaker consumer sentiment and declining sales in Japan and overseas continued as COVID-19 resurged, with actual effects on demand and the business environment.
  13. FY2021-Q2MaterialisedAnnual report

    「In addition to lower sales of sunscreen, lip balm and contact lens-related products due to restrictions on going out as COVID-19 spread, inbound demand also remained weak.」

    Restrictions on going out due to COVID-19 materialized as lower sales of seasonal and outdoor-related products in Japan and weak inbound demand, while sales declined in each overseas region as well.
  14. FY2021-Q1MaterialisedAnnual report

    「In Japan, sales of sunscreen, lip balm and contact lens-related products declined, partly because of restrictions on going out. Overseas sales also declined because of the global spread of COVID-19.」

    Restrictions on going out and the global spread of COVID-19 have materialized as lower sales of seasonal and outdoor-related products in Japan and lower overseas sales.
  15. FY2020First statedAnnual report

    「The global spread of COVID-19 has had serious effects, including disruption to supply chains centered on China, a decline in consumer activity and turmoil in financial markets, with no end in sight.」

    The company has identified supply chain disruption, declining consumer activity and financial market turmoil associated with the global spread of COVID-19 as new risks, stating that serious effects have already emerged. Its business and other risks also include the potential impact on results if restrictions on going out continue and personal consumption remains sluggish.
Moved together

"Growth in Overseas Revenue" moved the same way as this thread, in the same document, in 11 of its 15 moves.

11118887★123456
  1. ★This thread
  2. 1Growth in Overseas Revenue11×
  3. 2Collection Risk for Trade Receivables and Loans11×
  4. 3Technological Innovation and Strengthening the R&D Platform8×
  5. 4Active investment in new fields and research and development8×
  6. 5Improved profitability through efficient use of selling, general and administrative expenses and advertising expenses8×
  7. 6Globalization Centered on Asia and Expansion into Emerging Markets7×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Rohto Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.